Abstract
Mirion will report fiscal results on April 28, 2026 Post Market; investors expect improving top-line momentum and stable profitability as segment mix and cost discipline shape the outlook for the new quarter.
Market Forecast
Consensus for the April–June quarter points to revenue of 245.08 million US dollars, implying a 22.11% year-over-year increase, with forecast EBIT of 15.19 million US dollars (+388.26% YoY), and EPS of 0.095 (+21.15% YoY). Forecast commentary from the prior update indicates margin stabilization alongside a mid-to-high single-digit adjusted EPS cadence; the gross margin and net margin outlooks are not explicitly guided but are expected to remain broadly consistent with last quarter’s levels.
Industrial solutions remain the core revenue driver and are expected to benefit from resilient project pipelines, while Healthcare continues to provide a steady, higher-quality margin mix. The most promising area is Industrial, projected to lead in absolute revenue contribution as it scales from a 2025 base of 614.60 million US dollars, positioning it for outsized incremental growth.
Last Quarter Review
Mirion’s previous quarter delivered revenue of 277.40 million US dollars (+9.08% YoY), a gross profit margin of 48.74%, GAAP net profit attributable to the parent company of 17.30 million US dollars with a net margin of 6.24%, and adjusted EPS of 0.15 (-11.77% YoY).
Profitability improved sequentially on operating discipline, while cash generation benefited from favorable working-capital timing and completed integration initiatives. Industrial contributed 614.60 million US dollars and Healthcare 310.80 million US dollars in the last reported year’s mix, reflecting a 66%/34% split that underpinned stable blended margins.
Current Quarter Outlook (with major analytical insights)
Main business: Industrial Solutions
Industrial Solutions remains the anchor of Mirion’s revenue base, supported by multi-year program visibility in defense-related detection systems, nuclear lifecycle services, and energy infrastructure monitoring. Bookings and backlog conversion are poised to support double‑digit revenue growth, with carryover projects smoothing quarterly volatility. Execution on fixed‑price contracts and selective price pass‑through should protect unit economics, keeping gross margin broadly in line with the recent 48%–49% run-rate. Operating leverage is likely to emerge as logistics and supply-chain costs normalize, helping EBIT growth outpace sales growth, though the timing of project milestones can still create quarterly lumpiness that investors should be prepared for.
Most promising business: Healthcare
Healthcare offers a resilient mix with attractive recurring elements in dosimetry and patient safety solutions, complementing capital placements into radiotherapy QA and nuclear medicine workflows. While smaller in absolute revenue, the segment’s contribution to margin quality continues to improve as software and services penetration deepens. For the to‑be‑reported quarter, demand from oncology centers and installed‑base upgrades provides a constructive backdrop, and management’s emphasis on product refresh cycles and cross‑sell should support mid‑to‑high single‑digit growth on a year‑over‑year basis. Given the prior-year base of 310.80 million US dollars for Healthcare, incremental gains can contribute meaningfully to consolidated EBIT due to favorable gross-to-operating margin conversion.
Key stock price drivers this quarter
- Revenue trajectory versus the 22.11% YoY forecast will be the primary catalyst; any deviation tied to project timing in Industrial could move the shares.
- Margin resilience is the second pivot: investors will watch whether gross margin holds near the 48.74% prior-quarter level while EBIT scales to the 15.19 million US dollars forecast; cost discipline and mix will be decisive.
- EPS sensitivity to interest and tax lines remains a swing factor. Delivery on the 0.095 EPS estimate depends on operating leverage and limited below‑the‑line noise, while order intake updates and commentary on backlog composition could recalibrate second‑half expectations.
Analyst Opinions
Analyst commentary gathered over the recent period skews constructive, with a clear majority reiterating positive stances driven by accelerating revenue growth and improving EBIT visibility. Several well-followed institutions highlight the improving trajectory in Industrial project execution and stability in Healthcare recurring revenues as supportive of the near‑term setup. The bullish camp expects Mirion to at least meet its 245.08 million US dollars revenue estimate and achieve the projected 21.15% EPS growth, arguing that pricing actions, backlog conversion, and disciplined cost control provide cushion against project‑timing risks. Collectively, the positive view centers on the company’s ability to sustain mid‑to‑high teens revenue momentum while holding margins near recent levels, which, if realized, would validate the case for multiple support into the next two quarters.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments